RELIGRAST 300MG

Religrast 300mcg injection contains filgrastim as its active ingredient. This white blood cell growth factor, known as granulocyte-colony stimulating factor, has been approved by the FDA to lower the risk of febrile neutropenia (the occurrence of fever or infection due to a low white blood cell count) and to shorten the duration of neutropenia (a reduced white blood cell count) in individuals with non-myeloid cancer undergoing chemotherapy. Additionally, it is utilized to boost the white blood cell count and minimize the duration of fever in patients with acute myeloid leukemia.

Furthermore, it is administered to individuals receiving bone marrow transplants and those suffering from severe chronic neutropenia (a low count of neutrophils in the bloodstream). The Religrast 300mcg injection is also employed to prepare blood for leukapheresis (a procedure that removes specific blood cells). It is indicated to enhance survival chances for individuals exposed to significant radiation levels, which can severely harm the bone marrow. Other applications include aiding patients with advanced HIV infection, thereby reducing the risk of infections.

Religrast 300mcg injection is classified as a colony-stimulating factor medication. These medications function by assisting the body in producing a greater number of white blood cells. White blood cells are crucial for fighting infections. These cells are particularly vulnerable to the effects of chemotherapy, which can lead to a decrease in their numbers. A reduction in white blood cells may leave your body insufficiently equipped to fight off bacteria, increasing the risk of infection. It is important to inform your doctor if you have a history of liver disease, kidney issues, sickle cell anemia, or bone disorders. Common side effects may include fever, pain, rash, cough, shortness of breath, and nosebleeds.